[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"morbid-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:morbid-obesity":682},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,57,88,113,135,166,191,214,244,269,306,333,361,393,420,444,470,492,517,540,560,588,617,641,659],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100643888",false,"NCT07668765","GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity","Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment","GLP-PROCT","Inclusion Criteria:\n\n* Age ≥18 years\n* Morbid obesity (BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities)\n* Newly prescribed GLP-1 receptor agonist therapy\n* Ability and willingness to provide written informed consent\n* Ability to attend 3-month follow-up visit\n\nExclusion Criteria:\n\n* Inflammatory bowel disease\n* Perianal Crohn's disease\n* History of anorectal malignancy\n* Previous pelvic radiotherapy\n* Anorectal surgery within the previous 3 months\n* Pregnancy\n* Neurogenic bowel dysfunction\n* Inability to comply with follow-up visits\n* Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment\n* Active anorectal infection or abscess","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","3 Months","OBSERVATIONAL","Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.",[26,27,28,29,30],"Morbid Obesity","Anorectal Diseases","Drug-Related Side Effects and Adverse Reactions","Constipation","Diarrhea",[32,33,34,35,36,37,38,39,40,41,42,43],"GLP-1 receptor agonist","obesity","anorectal symptoms","hemorrhoids","anal fissure","constipation","semaglutide","tirzepatide","proctologic examination","bowel habits","anorectal disease","proctology","NOT_YET_RECRUITING","2026-06-23",{"date":47,"type":48},"2026-06-25","ACTUAL",{"date":50,"type":21},"2026-08",{"date":52,"type":21},"2027-05",{"name":54,"class":55},"Gazi University","OTHER",1,{"id":58,"slug":4,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":56},"100627310","NCT07446972","Impact of Bariatric Surgery on Female Sexual Function and Sex Hormones","Impact of Bariatric Surgery on Female Sexual Function, Sex Hormones, and Psychological Well-Being: A Prospective Cohort Study With Partner Assessment","Inclusion Criteria:\n\n* Female gender\n* Age 18-45 years (childbearing period)\n* Body Mass Index (BMI) ≥40 kg\u002Fm² or ≥35 kg\u002Fm² with obesity-related comorbidities, meeting international criteria for bariatric surgery\n* Scheduled for primary bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass)\n* Presence of a stable, sexually active intimate partner relationship\n* Sexually active\n* Willingness to participate and provide informed consent\n* Ability to complete Arabic-language questionnaires\n\nExclusion Criteria:\n\n* Women who are not sexually active\n* Post-menopausal women (amenorrhea ≥12 months without other cause)\n* Current pregnancy or lactation\n* History of medication use that can interfere with sexual function, including:\n* Antidepressants\n* Antipsychotics\u002Fpsychotropic drugs\n* Beta-blockers\n* Spironolactone\n* Hormonal contraceptives (unless stable for ≥3 months and continued throughout study)\n* Hormone replacement therapy\n* Major uncontrolled medical conditions:\n* Chronic heavy smoker (smoking index ≥400 pack-years)\n* History of pelvic floor surgery or gynecological malignancy\n* Partner with known erectile dysfunction or use of erectile dysfunction medications\n* Previous bariatric surgery (revisional procedures)\n* Inability or unwillingness to provide informed consent","FEMALE","45 Years",{"count":66,"type":21},40,"The goal of this observational study is to learn about how weight loss surgery (also called bariatric surgery) affects sexual function and sex hormone levels in women with severe obesity. It will also look at how the surgery affects mood, quality of life, body image, and the partner's sexual health.\n\nThe main questions it aims to answer are:\n\n* Does sexual function improve after weight loss surgery?\n* Do sex hormone levels change after weight loss surgery?\n* Are these changes linked to improvements in mood and quality of life?\n* Does the partner also experience changes in sexual function?\n\nResearchers will compare each participant's results before surgery to their results 6 months after surgery. This helps show how things change over time.\n\nThis study will include about 40 women who:\n\n* Are between 18 and 45 years old\n* Have severe obesity and are scheduled for weight loss surgery at Cairo University Hospital\n* Have a stable, sexually active partner relationship\n\nWhat participants will do:\n\n* Complete questionnaires about sexual function, mood, quality of life, and body image (twice: before surgery and 6 months after)\n* Provide a blood sample to measure sex hormone levels (before surgery and 6 months after)\n* Their partners will complete a short questionnaire about their own sexual function\n\nThis research is important because sexual health is a key part of quality of life that is often overlooked in obesity care. Understanding how weight loss surgery affects sexual function, hormones, and mood can help doctors better counsel patients about what to expect after surgery. This is one of the first studies in Egypt to examine these questions and the first to include partner assessment.\n\nThe study will start in January 2026. Results will be available by late 2026.",[26],[70,71,72,73,74,75,76,77],"Bariatric Surgery","Female Sexual Function Index","Sex Hormones","Beck Depression Inventory","Beck Anxiety Inventory","Quality of Life","Body Image","Partner Assessment","RECRUITING","2026-06-07",{"date":81,"type":48},"2026-06-10",{"date":83,"type":48},"2026-06-05",{"date":85,"type":21},"2027-02",{"name":87,"class":55},"Cairo University",{"id":89,"slug":4,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100558132","NCT06547138","Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)","Prospective Descriptive Multicentre Pilot Study On The Effectiveness and Safety Of Optilene® Silver Mesh Elastic In Prevention Of Surgical Site Infection (SSI) And Incisional Hernia (IH)","SSIHLVER","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Surgical procedure requiring urgent, primary median laparotomy, which are classified as \"Class III\u002FContaminated\" or \"Class IV\u002FDirty-Infected\" regarding the CDC classification.\n\nThese include but are not limited to:\n\n* Vascular surgery\n* Colon and rectum\n* Hepatobiliary\n* Gastrointestinal\n* Gynecology\n* Urology\n* Abdominal Aortic Aneurysm (AAA) repair\n* Right hemicolectomy\n* Left hemicolectomy\n* Sigmoidectomy\n* Anterior resection\n* Abdominoperineal amputation\n* Exploratory laparotomy\n* Cholecystectomy\n* Cholecystectomy and choledocotomy\n\n  * Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding\n* Patients \\\u003C 18 years old or patients who are still in the growth phase\n* Contaminated and infected areas\n* Hypersensitivity to silver\n* Direct contact with the viscera\n* Previous allergic reactions to components of the device\n* Patient with previous laparotomy\n* Transverse laparotomy\n* Patients with previous hernia repair\n* Simultaneous participation in another investigational clinical trial (drug or medical studies)\n* Patients with active oncologic treatment (chemo and radiotherapy)\n* Underlying autoimmune disease\n* Recent cardiovascular complication\n* Gynecology surgery\n* Urology surgery\n* Vascular surgery",{"count":96,"type":21},110,"The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.",[99,26],"Abdominal Aortic Aneurysm",[101],"urgent, primary median laparotomy","2026-06-01",{"date":104,"type":48},"2026-06-02",{"date":106,"type":21},"2026-09",{"date":108,"type":21},"2028-09",{"name":110,"class":111},"Aesculap AG","INDUSTRY",5,{"id":114,"slug":4,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100325442","NCT03517072","Determinants of the Long-Term Success of Bariatric Surgery","Determinants of the Long-Term Success of Bariatric Surgery \"- Multicenter Regional Observational Study: Regional Multicentre Prospective Study","PRECOS","Inclusion Criteria:\n\n* Patients who received bariatric surgery 5 years ago.\n\nExclusion Criteria:\n\n* Refusal to participate in the study,\n* Unable to receive informed information,\n* Unable to participate in the study",{"count":121,"type":21},1000,"The management of obesity is based on a multidisciplinary approach and justifies the use of surgery in patients with the most severe forms. Surgery for obesity or bariatric surgery generally allows rapid and significant weight loss however it is associated with significant risks, and its long-term results remain heterogeneous and unpredictable. Long-term data will clarify the role of different types of bariatric surgery in surgical strategy, improve patient information and identify predictors of failure in order to provide personalised and tailored surgery for each candidate .",[26,124],"Bariatric Surgery Candidate","2026-05-20",{"date":127,"type":48},"2026-05-22",{"date":129,"type":48},"2018-07-31",{"date":131,"type":21},"2027-01",{"name":133,"class":55},"University Hospital, Lille",4,{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100639410","NCT07602959","Investigation of the Effects of Whole Body Vibration Application on Muscle Functional Level, Physical Fitness and Respiratory Parameters After Bariatric Surgery","Inclusion Criteria:\n\n* Having undergone bariatric surgery, At least 6 weeks have passed since bariatric surgery, Being between the ages of 18-65, Being diagnosed with obesity and having a BMI\\>35, There is no obstacle that restricts exercise\n\nExclusion Criteria:\n\n* Acute hernia, Thromboembolism, Steroid use, Cardiovascular, neurological, orthopedic disease, Presence of knee or hip prosthesis, History of non-traumatic fracture, Presence of pacemaker, Malignancy, Presence of kidney, liver or thyroid disease, Presence of arrhythmia, Pregnancy status, Presence of kidney stones, Presence of epilepsy, Presence of migraine, Presence of organ failure, Presence of acute infection, History of smoking, Presence of respiratory system disease",true,"65 Years",{"count":143,"type":21},60,"INTERVENTIONAL",[146],"NA","The aim of this study was to investigate the effects of whole body vibration on muscle functional level, physical fitness and respiratory parameters after bariatric surgery.\n\nHypotheses of the study:\n\nH1: TVV after bariatric surgery has an effect on the functional level of the muscle.\n\nH2: TVV after bariatric surgery has an effect on physical fitness. H3: TVV after bariatric surgery has an effect on respiratory parameters. H4: TVV after bariatric surgery has an effect on quality of life. H5: TVV after bariatric surgery has an effect on body composition. H6: TVV after bariatric surgery has an effect on biochemical parameters.\n\nPatients will be divided into 3 randomized controlled groups. Whole body vibration application group, resistance exercise group and control group.\n\nThe whole body vibration group will exercise on the device 3 days a week. Resistance exercise group will exercise with resistance band 3 days a week. All exercises will last 6 weeks. The whole body vibration, resistance exercise and control groups will be recommended to walk 7 days a week.",[149,26,150],"Obesity & Overweight","Morbid Obesity Requiring Bariatric Surgery",[152,153,154,155,156,157],"bariatric surgery","whole body vibration","resistance exercise","physical fitness","respiration","functional level of muscle","2026-05-16",{"date":127,"type":48},{"date":161,"type":21},"2026-05-30",{"date":163,"type":21},"2026-09-01",{"name":165,"class":55},"Kirsehir Ahi Evran Universitesi",{"id":167,"slug":4,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":56},"100628436","NCT07461610","Stool Analysis After Sleeve Gastrectomy vs Gastric Bypass","Routine Stool Parameters Six Months After Sleeve Gastrectomy vs. Gastric Bypass: Correlation With Weight Loss and Metabolic Outcomes","Inclusion Criteria:\n\n* Male and female patients aged 18 to 60 years\n* Body Mass Index (BMI) ≥ 40 kg\u002Fm², OR BMI ≥ 35 kg\u002Fm² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, osteoarthritis, obstructive sleep apnea)\n* Patients scheduled for primary laparoscopic bariatric surgery (either SG or Gastric Bypass \\[MGB or RYGB\\]) at Kasr Al-Ainy University Hospitals\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or \\> 60 years\n* Previous bariatric surgery or major gastrointestinal surgery (gastric, intestinal, or colorectal resection)\n* Chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m²) or previous renal transplant\n* Chronic liver disease (cirrhosis, chronic hepatitis) or liver failure\n* Chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, or chronic pancreatitis\n* Active malignancy or history of chemotherapy\u002Fradiotherapy in the past 5 years\n* Pregnancy or breastfeeding\n* Chronic alcohol abuse or substance abuse\n* Use of antibiotics, probiotics, or prebiotics within 4 weeks prior to stool sample collection (to avoid confounding effects on gut flora)\n* Acute gastrointestinal infection at the time of sample collection","60 Years",{"count":174,"type":21},50,"The goal of this observational study is to learn whether routine stool tests can detect changes in gut function 6 months after two common types of weight loss surgery: sleeve gastrectomy and gastric bypass (including mini gastric bypass and Roux-en-Y gastric bypass). The main questions it aims to answer are:\n\nDo stool tests show more signs of undigested food or carbohydrate malabsorption after gastric bypass compared to sleeve gastrectomy?\n\nDo signs of gut inflammation in stool (like fecal calprotectin) decrease after surgery, and does this relate to improvements in blood sugar and weight loss?\n\nCan simple stool test results at 6 months predict how much weight a person loses or how well their diabetes improves?\n\nResearchers will compare stool test results between the two surgery groups (sleeve gastrectomy vs. gastric bypass) to see if the type of surgery leads to different changes in gut health.\n\nParticipants will:\n\nProvide a stool sample before surgery and again 6 months after surgery\n\nProvide a blood sample at the same time points to measure weight, blood sugar, and cholesterol\n\nUndergo their planned weight loss surgery as part of their regular medical care",[26],[70,178,179,180,181,182],"Stool Analysis","Fecal Calprotectin","Reducing Substances","Maldigestion","Gut Microbiota","2026-05-14",{"date":185,"type":48},"2026-05-18",{"date":187,"type":48},"2026-04-05",{"date":189,"type":21},"2026-12",{"name":87,"class":55},{"id":192,"slug":4,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":56},"100211065","NCT02024542","Metabolic Responses to Bariatric Surgery","Genetic and Biochemical Characteristics of Medically-Complicated Obesity and Response to Bariatric Surgery","Inclusion Criteria:\n\n* Meet NIH Criteria for Bariatric Surgery\n* Between the Age of 18-55\n* Dyslipidemia controlled with medication\n* Impaired glucose metabolism or type 2 diabetes\n\nExclusion Criteria:\n\n* Uncontrolled Metabolic syndrome (uncontrolled diabetes, htn, dyslipidemia), one or all conditions.","55 Years",{"count":199,"type":21},500,"Research the genetic and biomechanical markers of human adipose tissue on patients with morbid obesity. Additional tissue\u002Ffluid collection is also gathered during the time of surgery.",[26],[70,203,204,205,206],"Obesity","Metabolic syndrome","Diabetes","Liver Disease",{"date":185,"type":48},{"date":209,"type":4},"2011-02",{"date":211,"type":21},"2035-04",{"name":213,"class":55},"University of California, Davis",{"id":215,"slug":4,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100634623","NCT07542093","Bedside Lung Ultrasound to Monitor Lung Recruitment in Obese Patients","Use of Bedside Lung Ultrasound to Monitor Lung Recruitment Maneuvers During Mechanical Ventilation in Obese Patients","Inclusion Criteria:\n\n* Adult patients aged \\>18 years\n* BMI ≥ 33 kg\u002Fm² (morbid obesity)\n* Intubated and receiving invasive mechanical ventilation for any indication (elective surgery, respiratory failure, post-operative ICU admission)\n* Expected duration of mechanical ventilation ≥ 6 hours\n* Hemodynamically stable at enrollment: Mean Arterial Pressure (MAP) ≥ 65 mmHg without escalating vasopressor support\n* SpO₂ ≥ 85% on current ventilator settings\n* Written informed consent obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Known or suspected pneumothorax or bullous emphysema (contraindication to recruitment maneuvers)\n* Severe hemodynamic instability: MAP \\\u003C 60 mmHg or requiring high-dose vasopressors (norepinephrine \\> 0.3 mcg\u002Fkg\u002Fmin)\n* Active bronchopleural fistula\n* Recent thoracic or cardiac surgery (within 48 hours) where high airway pressures are contraindicated\n* Raised intracranial pressure (ICP) or known severe traumatic brain injury\n* Confirmed ARDS with PaO₂\u002FFiO₂ ratio \\\u003C 100 mmHg (severe ARDS, where recruitment strategy differs significantly)\n* Chest wall deformity or subcutaneous emphysema that precludes reliable lung ultrasound assessment\n* Refusal of consent",{"count":221,"type":21},45,"Patients with morbid obesity who require a breathing machine (mechanical ventilator) in the Intensive Care Unit (ICU) frequently experience partial lung collapse. This happens because the extra weight of the chest and abdomen presses on the lungs, reducing their capacity and making it difficult to maintain adequate oxygen levels. To address this, doctors often perform a standard lung recruitment maneuver, which involves temporarily increasing the air pressure from the ventilator to gently pop open the collapsed lung areas. However, standard bedside monitoring tools make it difficult to see exactly how well the different regions of the lungs are reopening.\n\nThis prospective observational study aims to evaluate the use of Bedside Lung Ultrasound (LUS), which is a safe, radiation-free imaging tool, to monitor how well the lungs respond to these maneuvers in real-time.\n\nDuring the study, researchers will use a standardized 12-zone ultrasound scan to examine the lungs of mechanically ventilated adult patients (BMI ≥ 33 kg\u002Fm²) before, during, and after a step-by-step lung recruitment maneuver. By calculating a \"Total Lung Ultrasound Score,\" the medical team can directly visualize and measure the transition from collapsed tissue to normal, aerated lung tissue. Furthermore, the ultrasound will be used during a step-down pressure phase to help identify the patient's \"optimal PEEP\" (Positive End-Expiratory Pressure), which is the exact customized pressure needed to keep the lungs open after the maneuver is complete, thereby improving oxygenation and minimizing the risk of lung injury.",[26,203,224,225,226],"Respiratory Failure","Atelectasis","Ventilator-Induced Lung Injury (VILI)",[228,229,230,231,232,233,234],"Lung Ultrasound (LUS)","Lung Ultrasound Score","Lung Recruitment Maneuvers (LRM)","Mechanical Ventilation","Positive End-Expiratory Pressure (PEEP)","Optimal PEEP","Decremental PEEP Titration","2026-04-14",{"date":237,"type":48},"2026-04-21",{"date":239,"type":21},"2026-05",{"date":241,"type":21},"2027-06",{"name":243,"class":55},"Assiut University",{"id":245,"slug":4,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":144,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":56},"100538658","NCT06293703","Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)","CLIMBII","Inclusion Criteria:\n\n* morbidly obese patients (defined by BMI between 40 and 60).\n* Patient who understands and accepts the need for a long-term follow-up.\n* Patient who agrees to be included in the study\n\nExclusion Criteria:\n\n* individuals unable to understand and sign a written consent form\n* patients with history of previous bariatric surgery procedures\n* presence of a severe and evolutive life threatening pathology unrelated to obesity\n* previous gastric or small bowel resection\n* active cancer\n* pregnancy or desired to be pregnant during the study\n* mentally unbalanced patients under supervision or guardianship, patient unable to give consent","70 Years",{"count":252,"type":21},262,[146],"The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics.",[26],[257,258,259],"Bariatric surgery","Roux-n-Y gastric bypass","gastric bypass","2026-03-18",{"date":262,"type":48},"2026-03-20",{"date":264,"type":48},"2024-01-12",{"date":266,"type":21},"2030-12-11",{"name":268,"class":55},"Salvador Navarrete",{"id":270,"slug":4,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":278,"conditions":279,"keywords":287,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":56},"100517290","NCT06015620","Comorbidities Resolution After MGB Surgery and Change in Body Composition","CoMOrbidities Resolution After Mini-GAstric Bypass Surgery for Morbid Obesity and Change in BOdy Composition: A Prospective Cohort Study (MOGAMBO Study)","MOGAMBO","Inclusion Criteria:\n\n* All patients undergoing laparoscopic MGB surgery for morbid obesity and it's associated comorbidities\n\nExclusion Criteria:\n\n* Patients not giving consent for the study\n* All patients who were undergoing a redo-procedure for recurrence were excluded from the study",{"count":277,"type":21},35,"This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are:\n\nTo study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition.\n\nOther objectives are:\n\n* Changes in the parameters of the metabolic syndrome after surgery\n* Changes in the cardiovascular risk biomarkers after metabolic surgery\n* Emergence in complications arising out of surgery requiring any intervention or causing a prolonged hospital stay, or requiring additional outpatient visits.\n\nType of Study: An observational study in which participants with morbid obesity will undergo mini-gastric bypass surgery as per routine protocol. No separate experimental interventions will be done in the study for the participants.",[26,280,281,282,283,284,285,286],"Type2diabetes","Sleep Apnea","Hypothyroidism","Hypertension","Lipid Disorder","Non-Alcoholic Fatty Liver Disease","Chronic Venous Hypertension With Ulcer",[288,289,290,291,292,293,294,295,296],"morbid obesity","OSA","mini gastric bypass","metabolic surgery","polysomnography","metabolic syndrome","DEXA scan","bioelectrical impedance","body composition","2026-02-16",{"date":299,"type":48},"2026-02-18",{"date":301,"type":48},"2023-09-01",{"date":303,"type":21},"2027-03-30",{"name":305,"class":55},"All India Institute of Medical Sciences, Bhubaneswar",{"id":307,"slug":4,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":144,"phases":314,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":56},"100526264","NCT06132477","Impact GLP-1 Agonists Following Bariatric","Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric","Inclusion Criteria:\n\n1. Greater than 18 years of age\n2. Participation in care by one of the surgeons at MU Health Care\n3. Undergoing surgical weight loss through the Weight Management and Metabolic Center\n4. Body mass index of 30-80 kg\u002Fm2\n5. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery or as a self-pay patient for the weight loss procedure\n6. Planned laparoscopic Roux-en-Y gastric bypass, sleeve gastrectomy, revisional weight loss surgery, or duodenal switch or modification of. If patients are not willing to be randomized they will not be enrolled as randomized but can still participate having samples collected.\n7. Willingness to have blood collected before and after surgical procedure at defined points or at minimum have clinical data collected.\n8. Willingness to have clinical data entered into a prospective database\n9. Additional specimens collected as stated in the protocol will be offered but collection not mandated.\n\n5\\. Taking a GLP-1 agonist as part of their routine medical care apart from any planned surgical procedure. The current standard of care regarding continuation or discontinuation of GLP-1 agonists has not been established and is at the discretion of members of the patient's medical team but to be included the patient and medical care team must be willing to continue or discontinue the GLP-1 agonist after surgery depending on the randomized group.\n\nExclusion Criteria:\n\n1. Pregnant patient\n2. Desire to not participate\n3. Age less than 18\n4. Patient fails to fulfill insurance mandated criteria and is not interested in paying cash for their procedure\n5. Not taking a GLP-1 agonist as part of standard medical care\n6. Unwilling to follow-up at required postoperative visits\n7. Unwilling to stop GLP-1 agonist if randomized into group to stop GLP-1 agonist or unwilling to continue the GLP-1 agonist if randomized into that respective group. If chooses to continue or discontinue the medication apart from randomization the patient can still participate as a non-randomized participant",{"count":313,"type":21},150,[315],"PHASE4","Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as well as superior to best medical therapy for treatment of diabetes not just through restriction of calories but also through a positive impact in modifications of gut hormones, changes in circulating bile acids, modifications in the gut microflora as well as other undefined mechanisms. The combined benefits of GLP1-RAs with bariatric surgery have only been studied to a limited effect. In this randomized trial, the effects of continuation or discontinuation of GLP1-RA therapy in patients undergoing bariatric surgery will be determined. We will compare changes in weight, metabolic determinants including circulating bile acids and gut microbiome, psychological determinants of eating behavior, and adverse side effects in patients who continue vs discontinue therapy. Given differences in metabolic and clinical outcomes in patients undergoing vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), both surgical groups will be examined. The study will be conducted at a high volume bariatric surgical program where patients will undergo randomization at the time of final clinic visit prior to surgery to continue or discontinue GLP1-RA. It is hypothesized that participants who continue GLP1-RA therapy after bariatric surgery will lose more weight with improved blood glucose control than those who discontinue therapy. Furthermore, changes in gut microbiome and circulating bile acids, known determinants of metabolic health, will be modified to a differential extent in those who are on GLP1-RAs vs those where GLP1-RAs are discontinued. Understanding the role these medications play in not only clinical outcomes after metabolic surgery but potential metabolic mechanisms by which surgery improves patient's metabolic health could help people with obesity and type 2 diabetes make informed decisions about their treatment options as well as advise providers on the continuation of these medications in the perioperative and postoperative period.",[26,318,319,283,320],"Metabolic Syndrome","Diabetes Mellitus","Obstructive Sleep Apnea of Adult",[322,26,70,204,319,283,323],"glp-1 agonist","Obstructive Sleep Apnea","2026-01-21",{"date":326,"type":48},"2026-01-22",{"date":328,"type":48},"2024-02-01",{"date":330,"type":21},"2030-07",{"name":332,"class":55},"University of Missouri-Columbia",{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":144,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":56},"100483026","NCT05569681","Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients","Comparison of Two Different Regimens of Bemiparin as a Thromboprophylaxis After Surgery in Morbidly Obese Patients: A Randomized, Outcome-assessor Blinded Trial.","Inclusion Criteria:\n\n1. Participants required surgical intervention in: general surgery, gynecology, bariatric surgery\n2. Moderate, high, and very high risk for venous thromboembolism according to Caprin RAM\n3. Participant is willing and able to give informed consent for participation in the study.\n4. BMI ≥40kg\u002Fm2\n\nExclusion Criteria:\n\n1. Having any contraindication to LMWH, such as active bleeding, history of heparin-induced thrombocytopenia , baseline platelet count \\\u003C75 × 108\u002Fμl, severe renal disease (glomerular filtration rate \\\u003C30 ml\u002Fminute), severe liver disease, or uncontrolled hypertension (\\>200\u002F120 mmHg)\n2. Known hypersensitivity to unfractionated or LMWHs\n3. On oral or parenteral anticoagulants within 5 days before surgery\n4. Severe arterial hypertension\n5. Unable to comply with the study treatment and\u002For follow-up\n6. Receiving prohibited medications\n7. Pregnancy or lactation mother","90 Years",{"count":341,"type":21},2400,[146],"Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.",[26],[346,347,348,349,350,351],"LMWH","Thromboprophylaxis","Non-orthopedic surgeries","Gynecological surgeries","General surgeries","Bariatric surgeries","2026-01-12",{"date":354,"type":48},"2026-01-13",{"date":356,"type":48},"2023-01-07",{"date":358,"type":21},"2026-10-02",{"name":360,"class":55},"Hawler Medical University",{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":144,"phases":371,"briefSummary":372,"conditions":373,"keywords":379,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":56},"100617855","NCT07324044","Chrono-ALIGN: A Chronotype-Based Chrono-Nutrition Intervention in Post-Bariatric Patients","Chrono-ALIGN Trial: The Impact of Chronotype-Based Chrono-Nutrition on Metabolic Health, Gut Microbiota, Appetite, and Circadian Alignment in Post-Bariatric Surgery Patients: A Randomized Controlled Trial","Chrono-ALIGN","Inclusion Criteria:\n\n* Adults aged 18-50 years who underwent Sleeve Gastrectomy (SG) 6 Months prior to enrollment.\n* Have achieved ≥50% of excess weight loss post-surgery (to ensure initial success).\n* Current BMI between 25-40 kg\u002Fm².\n* No major postoperative complications and cleared for a regular diet by their healthcare provider.\n* Participants must be able to align their eating schedule within a daytime window (morning to evening), ensuring that the first meal is consumed in the early part of the day and the last meal is completed before late evening, in accordance with chrono-nutrition guidelines.\n\nExclusion Criteria:\n\n* • Pregnancy or planned pregnancy during the study period, and post menopaused females\n\n  * Current diagnosis of severe psychiatric illness that may interfere with adherence (e.g., untreated major depression, psychosis, severe eating disorders).\n  * Active malignancy or serious chronic disease unrelated to obesity that may confound outcomes (e.g., advanced renal failure, uncontrolled liver disease).\n  * Use of medications known to significantly alter circadian rhythm or metabolism (e.g., corticosteroids, melatonin therapy) within the last 3 months.\n  * Inability to comply with study requirements (dietary interventions, sample collection, or follow-up visits).Participants who have previously undergone revision bariatric surgery.\n  * Individuals following intermittent fasting regimens prior to the study.","50 Years",{"count":370,"type":21},246,[146],"This randomized controlled trial will evaluate the impact of chrono-nutrition, a dietary approach that aligns meal timing with the body's circadian rhythms, on weight change, metabolic outcomes, appetite, and gut microbiota in post-bariatric surgery patients. A total of 246 adults who underwent sleeve gastrectomy at least six months earlier will be enrolled at King Saud Medical City. Participants will be randomized to receive either standard post-bariatric nutritional care or personalized chrono-nutrition based on individual chronotype. Outcomes include weight change, metabolic biomarkers, dietary behaviors, sleep patterns, and gut microbiota composition. The study aims to determine whether integrating chrono-nutrition into post-bariatric follow-up can enhance metabolic health and improve long-term health.",[374,26,375,376,377,378],"Obesity (Disorder)","Bariatric Sleeve Gastrectomy","Meal Time","Chronotype","Circadian Rhythm",[380,70,381,182,382,383],"chrononutrition","Gastric Sleeve","Appetite","Meal Timing","2025-12-23",{"date":386,"type":48},"2026-01-07",{"date":388,"type":21},"2026-01-01",{"date":390,"type":21},"2028-12-01",{"name":392,"class":55},"King Saud University",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":399,"targetDuration":4,"studyType":144,"phases":400,"briefSummary":401,"conditions":402,"keywords":405,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":56},"100615203","NCT07289555","Tailored Stapled SADI-S: Initial Report and Preliminary Results","Tailored Stapled Single Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): Initial Report and Preliminary Results","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* BMI ≥35 kg\u002Fm² or BMI ≥30 kg\u002Fm² with obesity-related comorbidities such as type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.\n* Willingness to adhere to follow-up visits and testing.\n* Indicated for revisional SADI-S post sleeve gastrectomy for inadequate weight loss or weight regain.\n\nExclusion Criteria:\n\n* Severe uncontrolled medical or psychiatric conditions preventing adherence to the protocol.\n* Known short bowel syndrome or previous extensive bowel resections or intraoperative finding of extensive bowel adhesions.",{"count":66,"type":21},[146],"Obesity is a serious health problem worldwide and can lead to many diseases such as diabetes, high blood pressure, heart disease, and sleep apnea. When lifestyle changes and medications are not enough, metabolic and bariatric surgery (MBS) is currently the most effective and long-lasting treatment option.\n\nThis study focuses on one of the newer types of bariatric surgery called Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). This procedure combines two parts:\n\nSleeve gastrectomy, which reduces the size of the stomach so the patient feels full after eating a small amount.\n\nDuodeno-ileal bypass, which shortens the path food takes through the small intestine to reduce calorie absorption.\n\nOur hospital's surgical team is studying a tailored version of this operation, where the length of the bypassed intestine is adjusted to each patient's anatomy. We believe this personalized approach may improve weight loss results while lowering the risk of vitamin and nutrient deficiencies.\n\nThe study will include 40 adult patients with obesity who are undergoing SADI-S surgery, either as their first weight loss operation or as a revision surgery after an earlier sleeve gastrectomy. During the operation, surgeons will measure the total length of each patient's small intestine and use a formula to decide how much of it should be bypassed. The duodeno-ileal connection will be made using a stapled technique, which is expected to be safe and efficient.\n\nAfter surgery, patients will be followed regularly at 1, 3, 6, 9, and 12 months, and then once per year. At each visit, the study team will monitor weight loss, body mass index (BMI), resolution of diabetes and other obesity-related conditions, nutritional status (including vitamins and minerals), and any side effects such as diarrhea, reflux, or nutritional problems.\n\nThe goal of this study is to learn whether this tailored SADI-S technique can provide strong, sustained weight loss and health improvement with fewer long-term complications. The results will help improve surgical planning for future patients by showing whether measuring and customizing the bypass length is safer and more effective than using a fixed length.\n\nAll data collected will be kept confidential. Patients' participation in the study will not change their regular care or follow-up, and they can withdraw at any time without affecting their treatment.",[26,70,403,404],"Malnutrition","Comorbidities",[406,257,407,408,409],"SADI-S","Limb length tailoring","Weight loss outcomes","Nutritional status","2025-12-04",{"date":412,"type":48},"2025-12-17",{"date":414,"type":48},"2024-06-01",{"date":416,"type":21},"2026-12-31",{"name":418,"class":419},"El-Sahel Teaching Hospital","OTHER_GOV",{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":17,"minAge":426,"maxAge":141,"enrollmentInfo":427,"targetDuration":429,"studyType":23,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":56},"100439338","NCT05000996","Gut Microbiota in Metabolic Surgery","The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study","Inclusion Criteria:\n\n* Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center\n* Have a history of type 2 diabetes, hypertension, or dyslipidemia\n* Be able and willing to provide personal information and biological samples needed for the study\n\nExclusion Criteria:\n\n* Prior gastric operations\n* A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis\n* Chemotherapy or radiotherapy for cancer within 2 years\n* Current inflammatory bowel disease or celiac disease\n* Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months","21 Years",{"count":428,"type":21},300,"10 Years","Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and\u002For tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.",[124,432,433,434,283,26],"Cardiovascular Diseases","Type 2 Diabetes","Dyslipidemias","2025-11-02",{"date":437,"type":48},"2025-11-04",{"date":439,"type":48},"2021-08-19",{"date":441,"type":21},"2035-01-01",{"name":443,"class":55},"Vanderbilt University Medical Center",{"id":445,"slug":4,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":449,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":469},"100255343","NCT02602769","Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome","Inclusion Criteria:\n\n* Children with ROHHAD syndrome\n\nExclusion Criteria:\n\n* Children with known genetic causes of obesity","2 Years","20 Years",{"count":452,"type":21},12,"Rapid onset Obesity, Hypoventilation, Hypothalamic dysfunction and Autonomic Dysregulation (ROHHAD) is a syndrome named in 2007. The hallmark of the syndrome is the rapid onset obesity and dysregulation of central ventilation. There is little information about the metabolic changes that lead to the rapid onset obesity in these children. The investigators would like to study the metabolic phenotype of these children to understand the disturbances in energy balance that lead to the rapid onset obesity.",[455,26],"Childhood Obesity",[457,458,459,460],"Hypoventilation syndrome","Hypothalamic dysfunction","Autonomic dysregulation","Rapid onsey obesity","2025-10-20",{"date":463,"type":48},"2025-10-21",{"date":465,"type":4},"2015-11",{"date":189,"type":21},{"name":468,"class":55},"Columbia University",2,{"id":471,"slug":4,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":144,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":56},"100604738","NCT07153419","Cost-Effectiveness and Outcome of Robot-assisted Vs Laparoscopic Roux-en-Y Gastric Bypass","Cost-Effectiveness and Outcome of Robot-assisted Vs Laparoscopic Roux-en-Y Gastric Bypass: A Non-inferiority Randomized Controlled Trial","LvRRYGB","Inclusion Criteria:\n\n* Age 18 years or older\n* Patients who are candidates for Roux-en-Y gastric bypass using a minimally invasive technique\n* Informed consent has been given.\n\nExclusion Criteria:\n\n* patients who are candidates for bariatric procedures other than Roux-en-Y gastric bypass, or to those who require a laparotomy for Roux-en-Y gastric bypass surgery.","75 Years",{"count":479,"type":21},512,[146],"The objective of this randomized controlled trial is to compare perioperative outcomes between laparoscopic and robotic approaches in patients with severe obesity who are candidates for RYGB. The trial aims to address the following key questions:\n\nTo evaluate the difference between the two procedures in terms of postoperative complications.\n\nTo assess intraoperative complications, conversion rate, mortality, operative times, postoperative hospital stay, and cost analysis for both approaches.\n\nIn summary, the researchers will compare the laparoscopic and robotic approaches to determine which one leads to better perioperative outcomes",[26],"2025-08-29",{"date":485,"type":48},"2025-09-04",{"date":487,"type":21},"2026-01",{"date":489,"type":21},"2028-10",{"name":491,"class":55},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":493,"slug":4,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":63,"minAge":18,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":144,"phases":500,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":56},"100531388","NCT06199154","Induction of Labor in Morbidly Obese Patients","Induction of Labor in Morbidly Obese Patients: Comparison of 50 mcg and 25 mcg Misoprostol - A Randomized Control Trial","Inclusion Criteria:\n\n* Morbidly obese (BMI ≥ 40 kg\u002Fm2) at admission for induction of labor\n* Speaks English or Spanish\n* Gestational age between 34 weeks and 0 days and 42 weeks and 6 days\n* Age 18 years old or older\n* Viable, single, cephalic fetus\n* Intent to proceed with cervical ripening - cervical exam: dilation \\\u003C 5 cm\n* Contractions \\\u003C 5 per 10 minutes\n\nExclusion Criteria:\n\n* History of cesarean delivery\n* Contraindication to prostaglandin administration (significant myomectomy, prior cesarean delivery)\n* Contraindication to vaginal delivery (placenta previa, vasa previa, HIV with high viral load)\n* Contraindications to labor (cardiac, neurosurgical, need for cesarean)\n* Age \\\u003C 18yo\n* Fetal growth restriction with abnormal umbilical artery Doppler indices\n* Cervical dilation \\>5 cm\n* Contractions \\>5 per 10 minutes\n* Significant vaginal bleeding with concern for placental abruption\n* Non-reassuring fetal status or fetal heart rate decelerations\n* Fetal demise or major fetal anomaly\n* Inability to give consent",{"count":499,"type":21},162,[501],"EARLY_PHASE1","The goal of this randomized control trial is to compare different doses of Misoprostol (25 mcg vs 50 mcg) in induction of labor (IOL) in morbidly obese patients with BMI \\>40. It is known that morbid obesity is a risk factor for failed IOL and ultimately cesarean delivery (CD.) If the rates of vaginal delivery in this population can improve, then surgical morbidity can be reduced in these patients.",[26,504],"Pregnancy",[506,288,507],"induction of labor","misoprostol","2025-07-02",{"date":510,"type":48},"2025-07-03",{"date":512,"type":48},"2024-07-15",{"date":514,"type":21},"2026-10",{"name":516,"class":55},"University of Maryland, Baltimore",{"id":518,"slug":4,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":63,"minAge":523,"maxAge":141,"enrollmentInfo":524,"targetDuration":4,"studyType":144,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":56},"100596871","NCT07051109","Dual-chamber Patient-controlled Analgesia for Postoperative Recovery","Comparison of Postoperative Recovery Between Dual-channel Pump for Intravenous Patient-controlled Analgesia(IV-PCA) and Conventional Single-channel Pump After Laparoscopic Sleeve Gastrectomy: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult females aged 19 to 65 years\n* American Society of Anesthesiologists physical status (ASA class) 1 to 3\n* Patients scheduled for laparoscopic sleeve gastrectomy under general anesthesia\n* Patients requesting the use of IV-PCA after surgery\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to the drugs used in this study (Ketorolac, Fentanyl)\n* Patients with alcohol or drug dependence, long-term use of opioids or analgesics\n* Patients with liver disease or renal failure\n* Patients with peptic ulcer, patients with gastrointestinal bleeding predisposition\n* Patients with suspected cerebrovascular hemorrhage, organic disorders of the head related to increased intracranial pressure\n* Patients with bronchial asthma or bronchospasm symptoms\n* Patients with severe respiratory depression\n* Nasal polyps, angioedema\n* Patients with or history of convulsive disease\n* Patients for whom the use of neuromuscular blocking agents is contraindicated","19 Years",{"count":525,"type":21},92,[146],"Postoperative nausea and vomiting (PONV) are the most common complications that can occur after general anesthesia. Postoperative use of opioids and morbid obesity have been reported as risk factors of PONV. In this study, the investigators aimed to compare the degree of postoperative side effects and pain control when an intravenous patient-controlled analgesia combining fentanyl and ketorolac via a dual-chamber device was provided to participants undergoing laparoscopic sleeve gastrectomy.",[26,529,530,531],"PCA","Analgesia","PONV","2025-06-25",{"date":510,"type":48},{"date":535,"type":48},"2022-10-11",{"date":537,"type":21},"2026-03-11",{"name":539,"class":55},"Seoul National University Bundang Hospital",{"id":541,"slug":4,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":56},"100595435","NCT07032415","The Effect of Cognitive Function Level in Morbidly Obese Patients","The Effect of a Nutrition Habit Change Program on Lifestyle and Cognitive Function Level in Morbidly Obese Patients","Inclusion Criteria:\n\n* Applying Kocaeli City Hospital's Obesity Center\n* Morbid Obesity\n* Completing the program\n\nExclusion Criteria:\n\n* People with psychiatric and neurological diseases\n* People using drugs",{"count":547,"type":21},77,"Obesity is a disease caused by many factors, such as lifestyle, eating habits, lack of physical activity, hormonal and genetic influences. These different factors make treatment planning difficult. Common treatments include changes in diet and lifestyle, medications, endoscopic methods (like balloon or botox), and surgery. No matter which method is used, the main goal is to help patients lose weight by creating a negative energy balance. To keep the weight off, patients need to maintain a balanced lifestyle in the long term.\n\nHowever, many treatments are not successful over time. One important part of long-term success is helping patients change their lifestyle and eating habits. A person's cognitive function may affect how they understand and follow these changes. Some studies show that a high body mass index (BMI) is linked to problems with thinking and memory. While weight loss may help improve brain function, the investigators don't yet know how early cognitive differences affect treatment results.\n\nAt the obesity center in our hospital, morbidly obese patients receive support from a team of doctors, dietitians, psychologists, and physiotherapists. For at least three months, they attend individual and group sessions to help change their lifestyle and eating habits. This study aims to see how patients' cognitive function affects how much weight they lose by the end of the program.",[203,26],[152,551],"cognition",{"date":553,"type":48},"2025-06-29",{"date":555,"type":21},"2025-07-22",{"date":557,"type":21},"2026-09-15",{"name":559,"class":419},"Kocaeli City Hospital",{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":567,"targetDuration":4,"studyType":144,"phases":569,"briefSummary":570,"conditions":571,"keywords":572,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":586,"locationsCount":469},"100499454","NCT05783466","Dairy Lipids and Cardiometabolic Risk","Bioactive Dairy Lipids to Manage Cardiometabolic Risk in Obesity","DAILICATE","Inclusion Criteria:\n\n* Men and women between 18-70 years\n* Body Mass Index (BMI) between 35 and 60 kg\u002Fm2 inclusive\n* Stable body weight (weight change +\u002F- 5 % for 3 months prior to screening)\n* Consumption of at least 1 serving\u002Fday of dairy products made from cow's milk\n* Informed consent\n\nExclusion Criteria:\n\n* History of bariatric or digestive surgery or disease interfering with main outcomes\n* Drinking more than 3 glasses of alcohol per day (\\>30g\u002Fday)\n* Pregnancy, parturiency or breastfeeding\n* Food allergies or intolerance to dairy products\n* Dietary restriction (vegetarian or lactovegetarian) or high protein diet\n* Use of dietary supplements\n* Treated with lipid lowering drugs (fibrates, statins, anti-PCSK9, ezetimibe, cholestyramine) within the last 6 weeks before study entry\n* Treated with insulin, GLP-1 analogs, acarbose, corticoids, beta-blockers.\n* Medications interfering with intestinal microbiota (beta-lactamines within 3 months before the study or laxatives)\n* Smoking ≥ 5 cigarettes\u002Fday during the past 6 months.",{"count":568,"type":21},75,[146],"It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group).\n\nMetabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.",[26],[203,573,574,575,576,577,578,579],"Nutrition","Dietary intervention","Weight loss","Metabolism","Dairy","Fat","Milk polar lipids","2025-06-13",{"date":582,"type":48},"2025-06-18",{"date":584,"type":48},"2023-06-28",{"date":514,"type":21},{"name":587,"class":55},"Hospices Civils de Lyon",{"id":589,"slug":4,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":595,"targetDuration":4,"studyType":144,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":469},"100587922","NCT06934681","Exercise to Fight Obesity","Impact of a Structured Physical Exercise Program on Body Composition in Morbid Obesity: A Randomized Controlled Trial","ExFO","Inclusion Criteria:\n\n* Age: 18-65 years\n* BMI ≥35 with comorbidities, or ≥40, regardless of comorbidity presence\n\nExclusion Criteria:\n\n* Participation in a structured physical exercise program within the past 6 months\n* Presence of musculoskeletal or systemic diseases that prevent participation in a physical exercise program\n* Uncontrolled hypertension\n* Uncontrolled diabetes, particularly in the presence of severe complications (neuropathy and\u002For diabetic foot, proliferative retinopathy)\n* Uncontrolled or unstable cardiovascular disease (acute myocardial infarction within the past year, angina, heart failure, peripheral artery disease)",{"count":596,"type":21},72,[146],"This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery.\n\nThe main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care. Furthermore, it also aims to evaluate other potentially affected aspects, such as body composition and functionality, quality of life, cardiovascular fitness, and various genetic and metabolic factors.\n\nThis study is a randomized clinical trial with two groups:\n\n* The intervention group will follow a structured exercise program both pre- and post- surgery.\n* The control group will receive standard care, including nutritional counseling and general health advice.\n\nThe study will include 72 adults with severe obesity (36 men and 36 women), all of whom will be randomly assigned to either the intervention or control group.\n\nParticipants in the exercise group will follow these steps:\n\n1. Before Surgery (Prehabilitation): A 26-week program with aerobic and strength exercises, done in-person or remotely 2-4 times per week.\n2. Pre-Surgery Maintenance: A flexible period before surgery where participants continue exercising on their own.\n3. After Surgery (Rehabilitation): A 20-week program focused on recovery and strength.\n4. Post-Surgery Maintenance: A long-term, self-guided phase to maintain progress.\n\nParticipants in the exercise group will also receive the same care as the control group, including nutrition counseling and medical checkups.\n\nTo evaluate participant progress, a series of measurements will be carried out, including:\n\n* BMI and body composition\n* Physical function assessed through isometric strength tests and other measures such as the Sit-to-Stand test and the 6-Minute Walk Test\n* Quality of life and lifestyle assessed using validated questionnaires\n* Daily physical activity measured with pedometers\n* Metabolic and genetic analysis from blood samples\n\nIf proven effective, this program could help establish structured exercise with telerehabilitation as a standard component of obesity care. The results may support the integration of exercise programs into clinical practice, leading to improved long-term outcomes for individuals with severe obesity undergoing bariatric surgery. Additionally, insights into genetic and metabolic factors may contribute to the development of personalized treatment strategies.",[26,70,600],"Telerehabilitation",[257,602,600,603,604,605,606,607],"Physical Exercise","Prehabilitation","Rehabilitation","Body composition","Morbid obesity","Functional capacity","2025-05-31",{"date":610,"type":48},"2025-06-04",{"date":612,"type":48},"2025-05-19",{"date":614,"type":21},"2029-04",{"name":616,"class":55},"Instituto de Investigacion Sanitaria La Fe",{"id":618,"slug":4,"hasResults":11,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":477,"enrollmentInfo":624,"targetDuration":4,"studyType":144,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":639,"locationsCount":56},"100435074","NCT04945473","Gastric Recalibration After Endoscopic Sleeve Gastroplasty","Assessment of the Impact of Endoscopic Gastric Revision by Application of Additional Sutures on Weight Loss After Endoscopic Sleeve Gastroplasty in Obese Patients","ESG-IRM","Inclusion Criteria:\n\n* Patients aged 18 to 75\n* Patients with morbid obesity (BMI≥ 30 with comorbidities or\\> 40)\n* Patients with obesity for more than 2 years\n* Failure of medical treatment of obesity\n* Patients who may benefit from general anaesthesia\n* Patient able to participate in all aspects of the study and that agree to comply with all study requirements, for the duration of the study. This includes the availability of reliable transportation and sufficient time to attend all follow-up visits.\n* Patient able to fully understand the study and ready to give consent to participate to the study.\n* Patient affiliated to the French social security system\n\nExclusion Criteria:\n\n* Patient with a contraindication to perform an ESG\n* Patient with a history of previous bariatric, gastric or esophageal surgery.\n* Patient who initiated medical therapy within the last 3 months, with evidence of weight gain.\n* Patient with an uncontrolled, poorly controlled, or suspected history of eating disorders or psychiatric illness.\n* Patient with unstable and precarious state of health, as determined and assessed by the investigator.\n* Patient who is pregnant, breastfeeding or of childbearing age and without effective contraception.\n* Patient in exclusion period (determined by a previous or ongoing study)\n* Patient under legal protection\n* Patient under guardianship or curatorship\n* Patients with a BMI less than 30 at 6 months after ESG. These patients will not be candidate for revision regardless of the randomization group.\n* Patients with a contraindication to MRI may be included in the study and will follow the \"No Imaging\" study design.",{"count":20,"type":21},[146],"Endoscopic sleeve gastroplasty (ESG) is a technique used for bariatric surgery, with results comparable to conventional surgery, in order to treat morbid obesity. It has also less risks of complications, and it is not an irreversible technique. It can be repeated overtime, regarding the evolution of the gastroplasty. There is little data in the literature on the effectiveness of endoscopic \"revision\". This study will assess the benefits and costs of a revision during the follow-up endoscopy.",[26],[33,629,630,631,632],"Endoscopy","ESG","Gastric emptying","Revision procedure","2025-04-29",{"date":635,"type":48},"2025-05-01",{"date":637,"type":48},"2021-07-13",{"date":106,"type":21},{"name":640,"class":55},"IHU Strasbourg",{"id":642,"slug":4,"hasResults":11,"nctId":643,"briefTitle":644,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":56},"100328340","NCT03554902","Endoscopic Gastric Tubulization","Endosleeve","Inclusion Criteria:\n\n* Patients scheduled for an endoscopic gastric tubulization in the Nouvel Hôpital Civil, Strasbourg, France",{"count":428,"type":21},"Endoscopic gastric tubulization is currently proposed in the Digestive Surgery Department of the Nouvel Hôpital Civil, Strasbourg, France, to adult patients with morbid obesity. The procedure is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA). It is standard practice since October 2016.\n\nThe objective of this study is to prospectively collect data of patients who underwent an endoscopic gastric tubulization, from last visit before procedure to 2 years after procedure. These data are usually collected during medical consultations and will enable the evaluation of weight loss, quality of life and comorbidities improvement, reproducibility and durability of the technique.",[26],[651,575,652],"Endoscopic gastric tubulization","Quality of life",{"date":635,"type":48},{"date":655,"type":48},"2018-06-08",{"date":657,"type":21},"2028-06",{"name":640,"class":55},{"id":660,"slug":4,"hasResults":11,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":140,"sex":17,"minAge":450,"maxAge":172,"enrollmentInfo":665,"targetDuration":4,"studyType":144,"phases":666,"briefSummary":667,"conditions":668,"keywords":669,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":673,"lastUpdatePostDateStruct":674,"startDateStruct":676,"completionDateStruct":678,"leadSponsor":680,"locationsCount":56},"100569053","NCT06689241","Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial","Inclusion Criteria:\n\n* Age: 20-60 years, both sexes.\n* ASA physical status class I to III.\n* BMI 35-50 kg\u002Fm²\n\nExclusion Criteria:\n\n* Severe cardiac disorder\n* chronic renal failure\n* liver cirrhosis\n* major psychological disorder",{"count":499,"type":21},[146],"Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\\_label randomized controlled trial",[26,124],[670,671,672],"venous thromboembolism","enoxaparin","rivaroxaban","2025-04-17",{"date":675,"type":48},"2025-04-22",{"date":677,"type":48},"2024-10-01",{"date":679,"type":21},"2026-05-01",{"name":681,"class":55},"Alexandria University",""]